Patents by Inventor Masaharu Seno
Masaharu Seno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220363777Abstract: An object of the present invention is to develop a technique of reducing cancer stem cells. The solution is to provide a human-derived anti-human Cripto-1 antibody containing specific amino acid sequences.Type: ApplicationFiled: November 10, 2020Publication date: November 17, 2022Applicants: GSP ENTERPRISE, INC., Tomoike Bio Ltd., A BIOTECH CO., LTD.Inventors: Masaharu SENO, Atsushi TAKAYANAGI, Sekyoung LEE
-
Patent number: 10682330Abstract: In order to reduce the side effects of paclitaxel derivatives having excellent anti-cancer effects, an attempt was made to produce a liposome encapsulating paclitaxel derivatives such as paclitaxel monoglycosides and docetaxel monoglycosides. However, the introduction efficiency of paclitaxel derivatives, etc., into a liposome was poor, and this technique was not developed to a practical level. The present invention provides a method for producing a liposome encapsulating a paclitaxel monoglycoside and/or a docetaxel monoglycoside, and having an antibody specifically recognizing a cancer cell, the method comprising a step of bringing a liposome encapsulating a polyoxyethylene ester derivative, a lower alcohol, and a buffer or water into contact with a solution in which a paclitaxel monoglycoside and/or a docetaxel monoglycoside is dissolved in an alkylene glycol-containing buffer or water.Type: GrantFiled: March 22, 2013Date of Patent: June 16, 2020Assignees: ENSUIKO SUGAR REFINING CO., LTD., HIROKI HAMADA, YOSHIO SHIMIZU, NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITYInventors: Hiroki Hamada, Ichiro Fujiwara, Masaharu Seno, Tomonari Kasai, Tsukasa Shigehiro, Masaharu Murakami, Katsuhiko Mikuni
-
Publication number: 20180280300Abstract: An object of the present invention is to provide a method for encapsulating a poorly water-soluble pharmacologically active substance in a liposome with high efficiency. The present invention provides a composition comprising a lipid having a phosphatidylcholine group, a cholesterol compound, a lipid having a phosphatidylethanolamine group, and a poorly water-soluble pharmacologically active substance, wherein the molar ratio of the lipid having a phosphatidylcholine group, the cholesterol compound, the lipid having a phosphatidylethanolamine group, and the poorly water-soluble pharmacologically active substance is 3 to 8:2 to 7:0.1 to 3:0.001 to 5, respectively.Type: ApplicationFiled: October 6, 2016Publication date: October 4, 2018Applicants: ENSUIKO SUGAR REFINING CO., LTD., National University Corporation Okayama UniversityInventors: Hiroki HAMADA, Masaharu SENO, Tomonari KASAI, Tsukasa SHIGEHIRO, Koji HARA, Tetsuya ITO, Ichiro FUJIWARA
-
Publication number: 20160256566Abstract: In order to reduce the side effects of paclitaxel derivatives having excellent anti-cancer effects, an attempt was made to produce a liposome encapsulating paclitaxel derivatives such as paclitaxel monoglycosides and docetaxel monoglycosides. However, the introduction efficiency of paclitaxel derivatives, etc., into a liposome was poor, and this technique was not developed to a practical level. The present invention provides a method for producing a liposome encapsulating a paclitaxel monoglycoside and/or a docetaxel monoglycoside, and having an antibody specifically recognizing a cancer cell, the method comprising a step of bringing a liposome encapsulating a polyoxyethylene ester derivative, a lower alcohol, and a buffer or water into contact with a solution in which a paclitaxel monoglycoside and/or a docetaxel monoglycoside is dissolved in an alkylene glycol-containing buffer or water.Type: ApplicationFiled: March 22, 2013Publication date: September 8, 2016Applicants: ENSUIKO SUGAR REFINING CO., LTD., NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITYInventors: Hiroki HAMADA, Ichiro FUJIWARA, Masaharu SENO, Tomonari KASAI, Tsukasa SHIGEHIRO, Masaharu MURAKAMI, Katsuhiko MIKUNI
-
Publication number: 20150079626Abstract: The present invention relates to a method of obtaining a cell population containing cancer stem cells, which comprises culturing iPS cells in the presence of culture supernatant of cancer cells.Type: ApplicationFiled: March 18, 2014Publication date: March 19, 2015Applicants: LSIP, LLC, National University Corporation Okayama UniversityInventors: Masaharu SENO, Akifumi MIZUTANI, Tomonari KASAI
-
Publication number: 20150056270Abstract: In order to reduce the side effects of paclitaxel derivatives having excellent anti-cancer effects, an attempt was made to produce a liposome encapsulating paclitaxel derivatives such as paclitaxel monoglycosides and docetaxel monoglycosides. However, the introduction efficiency of paclitaxel derivatives, etc., into a liposome was poor, and this technique was not developed to a practical level. The present invention provides a method for producing a liposome encapsulating a paclitaxel monoglycoside and/or a docetaxel monoglycoside, and having an antibody specifically recognizing a cancer cell, the method comprising a step of bringing a liposome encapsulating a polyoxyethylene ester derivative, a lower alcohol, and a buffer or water into contact with a solution in which a paclitaxel monoglycoside and/or a docetaxel monoglycoside is dissolved in an alkylene glycol-containing buffer or water.Type: ApplicationFiled: March 22, 2013Publication date: February 26, 2015Inventors: Hiroki Hamada, Ichiro Fujiwara, Masaharu Seno, Tomonari Kasai, Tsukasa Shigehiro, Masaharu Murakami, Katsuhiko Mikuni
-
Patent number: 7951379Abstract: The invention provides a therapeutic drug that uses hollow protein nanoparticles displaying an antibody against a specific cell or specific tissue. The effectiveness of the drug has been proved by animal testing. The invention also provides a therapeutic method using such a drug. In a drug according to the present invention, a substance to be transferred into a cell for treating a disease (for example, a cancer treating gene such as a thymidine kinase gene derived from simple herpes virus) is encapsulated in hollow nanoparticles of a particle-forming protein (for example, hepatitis B virus surface-antigen protein that has been modified to lack its infectivity to hepatocytes and display an antibody). The particle surface of the drug displays an antibody, such as a cancer specific antibody, that recognizes an antigen molecule displayed on the surface of a specific cancer cell.Type: GrantFiled: March 26, 2003Date of Patent: May 31, 2011Assignees: Japan Science and Technology Agency, Beacle, Inc.Inventors: Shunichi Kuroda, Katsuyuki Tanizawa, Toshihide Okajima, Akihiko Kondo, Masakazu Ueda, Masaharu Seno
-
Patent number: 7597905Abstract: As a versatile means for specifically and safely transporting and transferring substances (genes, proteins, compounds, etc.) into target cells and tissues, hollow nano particles comprising a protein capable of forming particles (e.g., hepatitis B virus surface antigen protein), and a biorecognition molecule introduced therein, are provided.Type: GrantFiled: February 9, 2001Date of Patent: October 6, 2009Assignee: Beacle Inc.Inventors: Shun'ichi Kuroda, Katsuyuki Tanizawa, Masaharu Seno, Akihiko Kondo, Masakazu Ueda
-
Publication number: 20090011036Abstract: The subject invention provides a disease-treating drug that uses hollow protein nanoparticles to specifically act on a target cell or tissue. The present invention allows a protein drug to be effectively capsulated in the particles. The invention also provides a therapeutic method using such a drug. The drug according to the present invention is capable of recognizing a specific cell, such as hepatocytes, and manufactured by fusing a disease-treating substance for a target cell (for example, interferon, hepatocyte growth factor etc.) with hollow nanoparticles of a particle-forming protein (for example, hepatitis B virus surface-antigen protein).Type: ApplicationFiled: November 30, 2007Publication date: January 8, 2009Inventors: Shunichi Kuroda, Katsuyuki Tanizawa, Akihiko Kondo, Masakazu Ueda, Masaharu Seno, Hiroko Tada
-
Publication number: 20060292118Abstract: The subject invention is hollow nanoparticles that comprise particle-forming first proteins (e.g. hepatitis B virus surface-antigen protein), containing a bio-recognizing molecule for recognizing a specific cell, wherein at least one of the first proteins interacts with a second protein (e.g. hepatitis B virus core-antigen protein) forming a capsid structure. With this structure, the present invention provides hollow nanoparticles, that allow transfer of a substance to a specific cell or tissue, and can be manufactured with stable productivity. The present invention further provides a drug made of the hollow nanoparticles.Type: ApplicationFiled: November 25, 2003Publication date: December 28, 2006Inventors: Shunichi Kuroda, Katsuyuki Tanizawa, Akihiko Kondo, Masakazu Ueda, Masaharu Seno
-
Publication number: 20060165726Abstract: The invention provides a disease-treating drug, specifically acting particular cells or tissues, which is based on protein hollow nanoparticles. The drug's therapeutic effects are confirmed through animal experiments. The invention also provides a treatment method using the drug. The disease-treating drug comprises a substance to be transferred into a cell for treatment of a disease (for example, cancer-treating, thymidine kinase gene of herpes simplex virus type 1) encapsulated in hollow nanoparticles containing particle-forming protein (for example, hepatitis B virus surface antigen protein modified to lose infectivity to inherent hepatocyte and also display a growth factor) displaying, for example, a growth factor.Type: ApplicationFiled: March 5, 2003Publication date: July 27, 2006Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Shunichi Kuroda, Katsuyuki Tanizawa, Akihiko Kondo, Masakazu Ueda, Masaharu Seno, Hidehiko Iwabuki
-
Publication number: 20060141042Abstract: The invention provides hollow nanoparticles of a protein with the ability to recognize specific cells such as the hepatocytes and to form particles (for example, hepatitis B virus surface-antigen protein), wherein the protein has a cysteine residue substituted to a different amino acid. The hollow nanoparticles have a stable particle structure and can be used to efficiently transfer substances to specific target cells or tissues. The invention also provides a drug using the hollow nanoparticles.Type: ApplicationFiled: June 27, 2003Publication date: June 29, 2006Inventors: Shunichi Kuroda, Katsuyuki Tanizawa, Akihiko Kondo, Masakazu Ueda, Masaharu Seno, Hiroko Tada
-
Publication number: 20060107338Abstract: The present invention provides a cirrhosis model animal having human hepatic tissues affected with cirrhosis. Anti-asialo GM1 antibodies are administered to a scid mouse which is an immune-deficiency animal, and its natural-killer-cell-dependent immune response capability is made defective, and then cirrhosis-patient-derived hepatic tissues are transplanted beneath a kidney membrane of the scid mouse, thereby producing the cirrhosis model animal. The cirrhosis model animal has the human hepatic tissues affected with cirrhosis, so that it is possible to use the cirrhosis model animal in development of a therapy and a therapeutic drug for cirrhosis.Type: ApplicationFiled: July 14, 2003Publication date: May 18, 2006Inventors: Shunichi Kuroda, Katsuyuki Tanizawa, Akihiko Kondo, Masakazu Ueda, Masaharu Seno
-
Publication number: 20060088536Abstract: The invention provides a therapeutic drug that uses hollow protein nanoparticles displaying an antibody against a specific cell or specific tissue. The effectiveness of the drug has been proved by animal testing. The invention also provides a therapeutic method using such a drug. In a drug according to the present invention, a substance to be transferred into a cell for treating a disease (for example, a cancer treating gene such as a thymidine kinase gene derived from simple herpes virus) is encapsulated in hollow nanoparticles of a particle-forming protein (for example, hepatitis B virus surface-antigen protein that has been modified to lack its infectivity to hepatocytes and display an antibody). The particle surface of the drug displays an antibody, such as a cancer specific antibody, that recognizes an antigen molecule displayed on the surface of a specific cancer cell.Type: ApplicationFiled: March 26, 2003Publication date: April 27, 2006Inventors: Shunichi Kuroda, Katsuyuki Tanizawa, Toshihide Okajima, Akihiko Kondo, Masakazu Ueda, Masaharu Seno
-
Publication number: 20060034869Abstract: The invention provides a drug for treating hepatic diseases with the use of hollow protein nanoparticles. The effectiveness of the drug has been proved by animal testing. The invention also provides a therapeutic method using such a drug. In a drug according to the present invention, a substance to be transferred into a cell for treating a hepatic disease (for example, a cancer treating gene such as a thymidine kinase gene derived from simple herpes virus) is encapsulated in hollow nanoparticles that have an ability to recognize a hepatocyte and are composed of a particle-forming protein (for example, hepatitis B virus surface-antigen protein).Type: ApplicationFiled: March 5, 2003Publication date: February 16, 2006Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Shunichi Kuroda, Katsuyuki Tanizawa, Akihiko Kondo, Masakazu Ueda, Masaharu Seno, Hidehiko Iwabuki
-
Publication number: 20060002901Abstract: A therapeutic composition for a disease caused by a failure in the survival, proliferation and/or differentiation of a cell which contains eosinophil cationic protein and other components; and a medium composition for promoting the survival, proliferation and/or differentiation of a cell.Type: ApplicationFiled: October 2, 2003Publication date: January 5, 2006Inventors: Masaharu Seno, Shun'ichi Kuroda, Katsuyuki Tanizawa, Midori Kitazoe, Miki Iwata, Toshitsugu Fujita, Nobuyuki Bokui
-
Publication number: 20050181064Abstract: The subject invention provides a disease-treating drug that uses hollow protein nanoparticles to specifically act on a target cell or tissue. The present invention allows a protein drug to be effectively capsulated in the particles. The invention also provides a therapeutic method using such a drug. The drug according to the present invention is capable of recognizing a specific cell, such as hepatocytes, and manufactured by fusing a disease-treating substance for a target cell (for example, interferon, hepatocyte growth factor etc.) with hollow nanoparticles of a particle-forming protein (for example, hepatitis B virus surface-antigen protein).Type: ApplicationFiled: March 5, 2003Publication date: August 18, 2005Applicant: Japan Science and Technology AgencyInventors: Shunichi Kuroda, Katsuyuki Tanizawa, Akihiko Kondo, Masakazu Ueda, Masaharu Seno, Hiroko Tada
-
Publication number: 20030092069Abstract: As a versatile means for specifically and safely transporting and transferring substances (genes, proteins, compounds, etc.) into target cells and tissues, hollow nano particles comprising a protein capable of forming particles (e.g., hepatitis B virus surface antigen protein), and a biorecognition molecule introduced therein, are provided.Type: ApplicationFiled: October 8, 2002Publication date: May 15, 2003Inventors: Shun?apos;ichi Kuroda, Katsuyuki Tanizawa, Masaharu Seno, Akihiko Kondo, Masakazu Ueda